Results 41 to 50 of about 396 (132)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

Clinical Endocrinology, Volume 93, Issue 5, Page 620-628, November 2020., 2020
Abstract Objective Somapacitan is a long‐acting, reversible albumin‐binding growth hormone (GH) derivative in development. This study aimed to evaluate the safety and efficacy of once‐weekly somapacitan versus daily GH over 52 weeks in Japanese patients with adult growth hormone deficiency (AGHD). Design Phase 3, multicentre, randomized, parallel‐group,
Fumio Otsuka, Yutaka Takahashi, Shigeyuki Tahara, Yoshihisa Ogawa, Michael Højby Rasmussen, Koji Takano   +5 more
wiley   +1 more source

Plain language summary - Effective growth hormone replacement with once-weekly somapacitan versus daily growth hormone in children with growth hormone deficiency: 3-year results from REAL 3

, 2022
A plain language summary for the publication Effective growth hormone replacement with once-weekly somapacitan versus daily growth hormone in children with growth hormone deficiency: 3-year results from REAL
Lars Sävendahl (9986312)
core   +1 more source

Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency. [PDF]

J Endocr Soc
CONTEXT: Once-weekly long-acting growth hormone (GH) analogue (LA-GHA) treatments offer an alternative to once-daily GH injections for the treatment of children and adults with GH deficiency (GHD).
Chen JV, Miller BS, Kelepouris N, Kennedy C, Wayser GR, Mason B, Yuen KCJ.   +6 more
europepmc   +2 more sources

Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-Analysis [PDF]

Advances in Therapy
Lasse de Fries Jensen, Vasileios Antavalis, Michael Hojby Rasmussen   +2 more
exaly   +2 more sources

Plain language summary for "Effective GH Replacement with Somapacitan in Children with GHD: REAL4 2-year Results and after Switch from Daily GH"

, 2023
Plain language summary for "Effective GH Replacement with Somapacitan in Children with GHD: REAL4 2-year Results and after Switch from Daily GH"
Rikke Beck Bang (16459941), Joanne Blair (9991035), Michel Polak (9991049), Jun Mori (701859), Reiko Horikawa (393659), Volker Böttcher (16459940), Michael Højby Rasmussen (14699299), Ho-Seong Kim (286495), Bradley S. Miller (12162545), Aristides K Maniatis (14172119)   +9 more
core   +1 more source

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency

Journal of the Endocrine Society, 2023
Abstract Context Growth hormone (GH) replacement therapy improves longitudinal growth and adult height in children with GH deficiency (GHD). GH stimulates insulin-like growth factor (IGF)-I release, the biomarker used for monitoring GH activity during treatment.
Rasmus J Kildemoes, Philippe F Backeljauw, Michael Højby, Joanne C Blair, Bradley S Miller, Jun Mori, Yassine K Lyauk   +6 more
openaire   +2 more sources

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients

Drug Design, Development and Therapy, 2022
Bradley S Miller,1 Kevin CJ Yuen2 1Pediatric Endocrinology, University of Minnesota Medical School, Minneapolis, MN, USA; 2Department of Neuroendocrinology and Neurology, Barrow Pituitary Center, University of Arizona College of Medicine and Creighton ...
Miller BS, Yuen KCJ
doaj  

Precision Dosing for Pediatric Growth Hormone Deficiency With Daily and Weekly Growth Hormone

MedComm, Volume 7, Issue 9, September 2026.
• This study supports precision dosing and switching between daily rhGH and weekly PEG‐rhGH in pediatric GHD. • Missed doses reduce treatment benefit more with daily rhGH than with weekly PEG‐rhGH. • The findings provide guidance for growth hormone dosing and monitoring in pediatric GHD.
Wei Wu, Chun‐Xiu Gong, Jie Mei, Ling Hou, Yan Liang, Yan‐qin Ying, Feng Ye, Ge‐Hang Ju, Hui‐Xiang Tian, Nan Yang, Yun Qin, Dongsheng Ouyang, Xiaoping Luo   +12 more
wiley   +1 more source

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

The Journal of Clinical Endocrinology & Metabolism, 2022
Abstract Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of somapacitan vs daily GH.
Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa   +10 more
openaire   +2 more sources

Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC‐HRMS/MS

Drug Testing and Analysis, Volume 18, Issue 7, Page 811-820, July 2026.
After evaluating the compatibility of the GH analogue redalsomatropin alfa with approved doping control immunoassays for rhGH, it was implemented into the existing detection method for somatrogon employing affinity purification with GHR‐Fc‐conjugated magnetic beads, tryptic digestion, and LC‐HRMS/MS to allow for a specific and sensitive detection ...
Katja Walpurgis, Andreas Thomas, Jasmin Thelen, Bettina Majer, Maneera Al‐Jaber, Wadha Abushareeda, Mario Thevis   +6 more
wiley   +1 more source